Tivic Health Systems, Inc. ( (TIVC) ) has released its Q2 earnings. Here is a breakdown of the information Tivic Health Systems, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tivic Health Systems, Inc. is a diversified immunotherapeutics company that leverages both biopharmaceutical and bioelectronic systems to address unmet medical needs, primarily focusing on immune system targeting therapies.
In its latest earnings report, Tivic Health Systems announced a strategic shift towards biopharmaceuticals, highlighted by its decision to exit the consumer healthtech market and focus on its late-stage clinical pipeline, particularly the development of its lead drug candidate, Entolimod™.
The company reported a decrease in revenue for the second quarter of 2025, totaling $86,000, compared to $140,000 in the same period of 2024, mainly due to reduced sales of its ClearUP™ device. Despite the revenue decline, Tivic achieved a higher gross margin of 67% compared to 42% in the previous year. Operating expenses increased to $2.0 million for the quarter, attributed to the expansion of its biopharmaceutical programs.
Tivic’s net loss for the second quarter of 2025 was $1.9 million, up from $1.3 million in the same quarter of 2024. The company raised $1.4 million through preferred equity and secured a $25 million equity line of credit to support its strategic initiatives.
Looking ahead, Tivic Health Systems is focused on advancing its biopharmaceutical programs, with management expressing confidence in the company’s transformation strategy to enhance shareholder value through the development and commercialization of its innovative therapies.